FDA Guideline to 21 CFR PART 211 SUB PART-D EQUIPMENT #21CFR #PART211 #EQUIPMENT #PBS #PBSINDIA

FDA Guideline to 21 CFR PART 211 SUB PART-D EQUIPMENT #21CFR #PART211 #EQUIPMENT #PBS #PBSINDIA GMP News, GMP guidelines, GMP Violations, GMP warnings, GMP Trends. A Public Health Global News Portal. (This story has not been edited by GMP Violations staff and is auto-generated from a syndicated feed/ experts experiences...

Read More

FDA GUIDE TO 21 CFR PART 211 AND SUB PARTS #FDAGUIDE #21CFR #PART211 #FORMULATIONS #GMP #PHARMAGUIDE

FDA GUIDE TO 21 CFR PART 211 AND SUB PARTS #FDAGUIDE #21CFR #PART211 #FORMULATIONS #GMP #PHARMAGUIDE FDA GUIDE TO 21 CFR PART 211 AND SUB PARTS #FDAGUIDE #21CFR #PART211 #FORMULATIONS #GMP #PHARMAGUIDE GMP News, GMP guidelines, GMP Violations, GMP warnings, GMP Trends. A Public Health...

Read More

FDA Warns Drug Facilities in China, Ireland, Australia and India

FDA Warning Letters go to Manufacturers in China, Ireland, Australia and India In the Month of May-2018 The US FDA has issued Warning Letters to pharmaceutical firms which not address cGMP practices The drug facilities are: Jilin Shulan Synthetic Pharmaceutical...

Read More

Alembic Pharma gets three observations from US FDA for Gujarat plant

Alembic Pharmaceuticals said none of the observations are related to data integrity or repetitive in nature Alembic Pharmaceuticals said the US health regulator has made three observations after inspecting its formulation facility in Panelav, Gujarat. “The...

Read More

FDA has issued form 483 to Dr. Reddy's Laboratory | API | IDA Bollaram | GMP VIOLATIONS |

FDA has insured form 483  to Dr. Reddy's Laboratory | API | IDA Bollaram | GMP VIOLATIONS | The US FDA has been inspected the Dr. Reddy's laboratory located at IDA Bollaram which is manufacturing of Active pharmaceutical ingredients. The form 483 has been issued...

Read More

CIPLA gets 483 by U.S. FDA For Goa Unit | CIPLA 483 | FDA |

Cipla Ltd. received eight observations regarding manufacturing practices at its Goa plant that contributes a quarter of the drugmaker’s sales in the U.S. The facility of India’s second-largest pharma company by market value was inspected from Jan. 22 -25,...

Read More

FDA Guide to Equipment design, size, and location 211.63

FDA Guide to Equipment design, size, and location 211.63 Subpart D--Equipment Sec. 211.63 Equipment design, size, and location Equipment used in the manufacture, processing, packing, or holding of a drug product shall be of appropriate design, adequate size, and...

Read More